With the reignited push for manned spaceflight and the development of companies focused
on commercializing spaceflight, increased human ventures into space are inevitable …

Since the discovery of myostatin (MSTN; also known as GDF-8) as a critical regulator of
skeletal muscle mass in 1997, there has been an extensive effort directed at understanding …

Importance The potential benefit of novel skeletal muscle anabolic agents to improve
physical function in people with sarcopenia and other muscle wasting diseases is unknown …

Exercise is a well-known non-pharmacological intervention to improve brain functions,
including cognition, memory, and motor coordination. Contraction of skeletal muscles during …

Background Skeletal muscle atrophy is a severe condition that involves loss of muscle mass
and quality. Drug intake can also cause muscle atrophy. Biguanide metformin is the first‐line …

Myostatin (MSTN) is a well-reported negative regulator of muscle growth and a member of
the transforming growth factor (TGF) family. MSTN has important functions in skeletal muscle …

Growth and differentiation factor 8 (GDF8) is a TGF-β superfamily member, and negative
regulator of skeletal muscle mass. GDF8 inhibition results in prominent muscle growth in …

Myostatin is a negative regulator of skeletal muscle growth secreted by skeletal myocytes. In
the past years, myostatin inhibition sparked interest among the scientific community for its …

Skeletal muscle wasting occurs in a variety of diseases including diabetes, cancer, Crohn's
disease, chronic obstructive pulmonary disease (COPD), disuse, and denervation. Tumor …

Myostatin (GDF-8) was discovered 25 years ago as a new transforming growth factor-β
family member that acts as a master regulator of skeletal muscle mass. Myostatin is made by …